BioRestorative Therapies Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume16.60 million shs
Average Volume46.41 million shs
Market Capitalization$10.72 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BioRestorative Therapies logo

About BioRestorative Therapies

Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The firm is developing the following scientific programs: brtxDISC, which offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures; and ThermoStem, which involves in the use of a cell-based, brown adipose tissue construct, treatment for metabolic disease, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. Its products are sold under the BRTX-100, ThermoStem and Stem Pearls as its trademarks. The company was founded on June 13, 1997 and is headquartered in Melville, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.32 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BioRestorative Therapies (OTCMKTS:BRTX) Frequently Asked Questions

What stocks does MarketBeat like better than BioRestorative Therapies?

Wall Street analysts have given BioRestorative Therapies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioRestorative Therapies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioRestorative Therapies' next earnings date?

BioRestorative Therapies is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for BioRestorative Therapies

How has BioRestorative Therapies' stock been impacted by Coronavirus?

BioRestorative Therapies' stock was trading at $0.0003 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BRTX shares have increased by 966.7% and is now trading at $0.0032.
View which stocks have been most impacted by COVID-19

Who are BioRestorative Therapies' key executives?

BioRestorative Therapies' management team includes the following people:
  • Lance Alstodt, Chairman, President & Chief Executive Officer
  • Francisco J. Silva, Secretary, Director & VP-Research & Development
  • Robert Paccasassi, Vice President-Quality & Compliance

Who are some of BioRestorative Therapies' key competitors?

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

What is BioRestorative Therapies' stock symbol?

BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."

How do I buy shares of BioRestorative Therapies?

Shares of BRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioRestorative Therapies' stock price today?

One share of BRTX stock can currently be purchased for approximately $0.00.

How much money does BioRestorative Therapies make?

BioRestorative Therapies has a market capitalization of $10.72 million and generates $80,000.00 in revenue each year.

How many employees does BioRestorative Therapies have?

BioRestorative Therapies employs 5 workers across the globe.

What is BioRestorative Therapies' official website?

The official website for BioRestorative Therapies is www.biorestorative.com.

Where are BioRestorative Therapies' headquarters?

BioRestorative Therapies is headquartered at 40 MARCUS DRIVE, MELVILLE NY, 11747.

How can I contact BioRestorative Therapies?

BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at (631) 760-8100 or via email at [email protected].

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.